5-hydroxyindole-3-carboxylate derivatives and uses thereof

Details 5-hydroxyindole-3-carboxylate derivatives and uses thereof 5-hydroxyindole-3-carboxylate derivatives and uses thereof

2011-06-14

2011-06-14

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S492000

Reexamination Certificate

active

07960427

ABSTRACT:
The present invention relates to 5-hydroxy-indole-3-carboxylate derivatives of formula I, or racemic mixture or optical isomers or pharmaceutically acceptable salts and/or hydrates thereof,wherein: substituents R1, R2, Z, X and Y are as defined in the description. The compounds of formula I can be useful for preparation of medicament for treatment and/or prophylaxis of virus infections, especially for preparation of medicament for anti-HBV (Hepatitis B virus) and anti-HIV (Human immunodeficiency virus).

REFERENCES:
patent: 5198552 (1993-03-01), Trofimov et al.
patent: 1685933 (1991-10-01), None
patent: WO 90/08135 (1990-06-01), None
patent: WO 02/072549 (2002-09-01), None
STN Registry No. 25901-02-4 (entered Nov. 16, 1984).
Han (Advances in Characterization of Pharmaceutical Hydrates. Trends in Bio/Pharmaceutical Industry, pp. 25-29. Mar. 2006).
Vippagunta et al (Adv Drug Deliv Rev 48:3-26, 2001).
Trofimov et al (Khimiko-Farmatsevticheskii Zhurnal 3(11):25-29, 1969) as evidenced by the attached STN Report (Accession No. 1970:90181).
STN Report (Accession No. 1993:661973—containing Trofimov et al (Khimiko-Farmatsevticheskii Zhurnal 27(5):23-24, 1993)).
Williams et al (Foye's Principles of Medicinal Chemistry, pp. 59-61, 2002).
Patani et al (Chem Rev 96:3147-3176, 1996).
Fadeeva, N. et al. (1993) “Inhibitors of the early stages of virus-cell interactions among derivatives of 3-ethoxycarbonyl-5-hydroxy-6-bromoindole” Khimiko-farmasevticheskii Zhurnal 26:17-20.
Grinev, A. et al. (1987) “Synthesis and antiviral activity of 2-alkylaminomethyl derivatives of 5-oxyindole” Khimiko-farmasevticheskii Zhurnal 21:52-55.
Mezentseva, M. et al. (1991) “Synthesis and antiviral activity of 2-phenoxymethyl derivatives of 5-hydroxyindole” Khimiko-farmasevticheskii Zhurnal 25:35-37.
Mezentseva, M. et al. (1991) “Synthesis and antiviral activity of 2-anilinomethyl derivatives of 5-hydroxyindole” Khimiko-farmasevticheskii Zhurnal 24:52-53.
Panisheva, E. et al. (1988) “Synthesis and biological activity of 5-oxy-6-bromoindole substitutes” Khimiko-farmasevticheskii Zhurnal 22:565-569.
Wang, D. et al. (2004) “Synthesis and in vitro antiviral activities of some new 2-arylthiomethyl-4-tertiaryaminomethylsubstituted derivatives of 6-bromo-3-ethoxycarbonyl-5-hydroxyindoles” Chinese Chemical Letters 15:19-22.
Zotova, S. et al (1995) “Synthesis and antiviral activity of indole and benzofuran sulfides” Pharmaceutical Chemistry Journal 29:57-59.
Zotova, S. et al. (1992) “Synthesis and biological activity of substituted sulfides of indole and benzofuran” Khimiko-farmasevticheskii Zhurnal 26:52-55.
Bean, P. 2005 “New Drug Targets for HIV”Clinical Infectious Diseases41:S96-100.
Casiday, R. et al. 1998 “Drug Strategies to Target HIV: Enzyme Kinetics and Enzyme Inhibitors, Chemical Kinetics Experiment” retrieved from http://www.chemistry.wustl.edu/˜edudev/LabTutorials/HIV/DrugStrategies.html.
Chai, H. et al. 2005 “Synthesis and in vitro anti-hepatitisu B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates”Bioorganic&Medicinal Chemistry14:911-917.
Cianci, C. et al. 2005 “Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor”Journal of Antimicrobial Chemotherapy55:289-292.
Crumpacker, C.S. et al. 2002 “New anti-HSV therapeutics target the helicase-primase complex”Nature Medicine8(4):327-328.
De Clercq, E. 2000 “Molecular Targets for Antiviral Agents”Journal of Pharmacology and Experimental Therapeutics297:1-10.
Gariss, P.C. 2009 “Ribosomal frameshifting: An emerging drug target for HIV”Current Opinion in Investigational Drugs10(2):121-128.
Ghany, M. et al. 2007 “Drug Targets and Molecular Mechanism of Drug Resistance in Chronic Hepatitis B”Gastroenterology132:1574-1585.
Liuzzi, M. et al. 2005 “Inhibitors of Respiratory Syncytial Virus Replication Target Cotranscriptional mRNA Guanylylation by Viral RNA-Dependent RNA Polymerase”Journal of Virology79(20):13105-13115.
Maltezou, H.C. et al. 2009 “Antiviral Agents for Influenza: Molecular Targets, Concerns of Resistance, and New Treatment Options”Curretn Drug Targets10(10):1041-1048.
Richardson, J.Y. et al. 2005 “Respiratory Syncytial Virus (RSV) Infection Induces Cyclooxygenase 2: A Potential Target for RSV Therapy”Journal of Immunology174:4356-4364.
Stein, L.L. et al. 2009 “Drug Targes in Hepatitisu B Virus Infection”Infectious Disorders—Drug Targets9(2):105-116.
Sung, W-K. et al. “2009 Deregulated Direct Targets of the Hepatitis B Virus (HBV) Protein, HBx, Identified through Chromatin Immunoprecipitation and Expression Microarray Profiling”Journal of Biological Chemistry284(33):21941-21954.
Zhao, C. et al. 2006 “Synthesis and in vitro anti-hepatitis B virus activites of some ethyl 5-hydroxy-1H-indole-3-carboxylates”Bioorganic&Medicinal Chemistry14:2552-2558.

Affiliated with

Also associated with

Rating

5-hydroxyindole-3-carboxylate derivatives and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-hydroxyindole-3-carboxylate derivatives and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-hydroxyindole-3-carboxylate derivatives and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2693208